676 / 1068
- Feasibility and promising results reported on the first 25 patients
(Passoni Int J Rad Oncol Biol Phys 2013): 3/25 G3 GI (12%); full
RT,Oxal,5FU dose in 96%, 96%, 88% of pts; no other G3 tox; 2 cCR pts
refused surgery: (8%); pCR: 7/23 (30%); TRG
≥
3: 21/23 (91%);
- Major response rate (cCR+pCR+TRG3 with viable cells ≤10%): 21/25
(84%)
- Updated results on 62/78 pts confirmed these results (G3 GI: 13.5%;
pCR+cCR: 29%, Major response rate: 79%
ART: clinical results
- Room for further dose escalation ?
- Individualizing the ART boost based on the early response ?